A developer of multi-functional drug platforms

Introduction to Filamon
A biotech incubator for major pharmaceutical companies


  • U.S. and Australian institutional research collaborations
  • Two clinical-stage candidates, one advanced pre-clinical stage
  • Current focus on the improvement and extension of lives of prostate cancer patients with metastatic disease

Filamon is commencing with three drug candidates:
 FLM-JG1 & FLM-c2 and FLM- BT2

All three involve ground-breaking discoveries that have eluded major pharma companies.

Our strategy is considerably de-risked with FLM-c2 already in the clinic and FLM-JG1 a repurposed drug with global marketing approval.

Together, Filamon believes all three technologies hold the key to halting the march of a cancer that kills an estimated 300,00 men globally each year.

At Filamon we are responding to the slow progress being made in the treatment of many of the most common, debilitating diseases in modern society, all of which represent both enormous burden on lives and enormous commercial potential:


Which becomes incurable once it becomes aggressive (invasive) and metastatic (spreading).

Autoimmune Disease

Over 80 different autoimmune diseases - most of which remain poorly treated or untreated.

Neurodegenerative diseases and conditions

Over 200 different neurodegenerative diseases and conditions including Parkinson's, Alzheimer's disease, and drug addiction - almost all of which remain poorly treated

Changing the paradigm to change the outcome

Albert Einstein famously said, “The world as we have created it is a process of our thinking. It cannot be changed without changing our thinking.”

Filamon is bringing change to the way we think about treating complex diseases like cancer, autoimmune and neurodegenerative diseases. We want to make quantum leaps forward instead of the current small steps.

We are pursuing the concept of multi-functional drugs …… drugs designed to achieve real progress that help to restore patients to living a normal, productive life.

Complex, multi-part diseases where each part involves a separate malfunction need drugs capable of correcting as many of those parts as possible.

Take for example the many parts of a cancer.

  • Only about half the cells in a tumour are cancer cells. The other half are cells hijacked from neighbouring healthy tissues and made to support the cancer cells. These include blood vessels, immune cells, fibroblasts, fat cells and even nerve cells, all contributing to the survival and growth of the tumour.
  • All topped off by potentially dozens of different genetic mutations in cancer cells from over 300 known cancer mutations to select from.

Curing an aggressive cancer needs a lot more than killing the cancer cells. It also involves:

  • Shutting down the inflammatory process that recruits all the support cells
  • Restoring cancer-killing immune function
  • Killing the highly resistant cancer stem cells that keep feeding replacement cancer cells.

Faced with this complexity of cellular and tissue errors, using drugs designed to block single malfunctions is unlikely to do anything more in most patients than delay the inevitable. And yet that is what is happening currently in cancer and autoimmune diseases with a focus on drugs called targeted medicines – or drugs designed to target single parts of this multi-part disease.

Filamon′s multi-functional medicine concept is the next rational step beyond targeted medicine. Multi-functional medicine by definition is where a single drug corrects multiple malfunctions in the one disease, multiplying the chances of successfully treating complex diseases such as cancer and chronic inflammatory diseases including autoimmunity.

Beyond offering the potential to revolutionise the treatment of diseases such as cancer, individual multi-functional medicines also have the ability to work across multiple diseases.

The diseases that Filamon is targeting with its multi-functional drugs have considerable overlap in their underlying malfunctions.

Filamon is building a pipeline of multi-functional drugs to revolutionise the treatment of cancer and widespread inflammatory/autoimmune and neurodegenerative diseases and conditions based on three proprietary drug technology platforms:

Tribbles 2 inhibition

Learn more

hGIIA-sPLA2 inhibition

Learn more

JUN-FosB/ΔFosB modulation

Learn more
The Science
The Pipeline
The Literature